BioTech Valuation Multiples
Explore private market BioTech valuation multiples with benchmarks structured by stage and region. Updated quarterly.
BioTech
BioTech companies software, infrastructure, and applications that enable prediction, automation, and decision support at scale. Private market AI valuations are often influenced by model differentiation, data advantages, compute intensity, and the ability to translate innovation into repeatable commercial traction.
The category spans foundational models, applied AI products, workflow copilots, and enabling infrastructure. DealMatrix tracks valuation dynamics across 7 funding stages and all major global regions, updated every quarter.
Sector
BioTech
Health & Life Sciences
Sector tracked since
2000
25+ years of data
EV/SALES & EV/EBITDA ACROSS
6 Regions · 7 Stages
Modelled independently via proprietary econometric approach
UPDATE FREQUENCY
Quarterly
Data updates & model improvement
BioTech Valuation Multiples
Select a region and funding stage to preview how BioTech companies are valued in private markets. Full data available on the platform.
The Venionaire DealMatrix Multiples Model
DealMatrix multiples are derived through a five-step model combining public capital market comparables, proprietary VC/PE/M&A transaction data, and macroeconomic indicators.
The model produces three components: The reported public multiple, the model-predicted multiple, and the lower bound predicted multiple averaged into the DealMatrix Composite, then adjusted for region and funding stage. The methodology follows the IPEV Guidelines 2025.
Isomorphic Labs Series B: Isomorphic Labs raised $2.1 Billion funding to scale its AI drug design engine
raised
Valuation
CellCentric Funding: CellCentric Raises $220M for a ‘transformative’ multiple myeloma medicine
raised
Valuation
Adcendo Series C: $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipeline
raised
Valuation
Italian biotech AAVantgarde adds $141M series B to fund retinal disease gene therapy trials
raised
Valuation
Munich-based Tubulis secures €308 million to advance antibody-drug conjugate innovation
raised
Valuation
Munich-based Tubulis secures €308 million to advance antibody-drug conjugate innovation
raised
Valuation
Health & Life Sciences
Pharmaceutical
Health & Life Sciences
MedTech
